Pharma News
Pharmaceutical
German drugmaker Bayer has revealed positive late-stage results for its investigational once-daily oral anticoagulant asundexian. 6 February 2026
Pharmaceutical
The US Federal Trade Commission has hailed what it calls a ‘landmark settlement’ with one of the nation’s largest pharmacy benefit managers (PBMs), Express Scripts, and its affiliated entities. 5 February 2026
Pharmaceutical
The US Department of Health and Human Services (HHS) has sharply expanded its use of artificial intelligence, listing around 450 AI use cases across the department in a newly published fiscal 2025 inventory. 4 February 2026
Most Read
Recent news
Pharmaceutical
Shares of BridgeBio Pharma were up 8.3% at $79.41 this morning, after it unveiled promising results for its most hotly debated final-phase asset: a potential treatment for achondroplasia, the most common form of dwarfism. 12 February 2026
Pharmaceutical
For the entire 2025 fiscal year, French drugmaker Ipsen’s revenues rose by 8.1%, or 10.9% at constant exchange rates, reaching a total of 3.68 billion euros ($4.37 billion). 12 February 2026
Pharmaceutical
Japanese drugmaker Nxera Pharma today notes that UK based Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. 12 February 2026
Pharmaceutical
Given increasing investor interest in novel, long-acting HIV treatment regimens, Leerink Partners analyst Daina Graybosch has publishing figures comparing the pipelines of Gilead, GSK and Merck & Co. 12 February 2026
Pharmaceutical
French pharma major Sanofi's board of directors has decided not to renew the director mandate of Paul Hudson. As a result, Paul Hudson’s last day as chief executive (CEO) will be on February 17, 2026 at the end of business. 12 February 2026
Refine search
In Brief
Pharmaceutical
27 January 2026 The US Department of Health and Human Services (HHS) has ended the permitted use of human fetal tissue from elective abortion in agency-funded research, applying the policy across all grants, contracts, and programs it oversees.
Pharmaceutical
19 January 2026 French nephrology specialist Advicenne has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Sibnayal (ADV7103), a fixed combination of potassium citrate and potassium bicarbonate for the treatment of distal renal tubular acidosis (dRTA).
Insights
Pharmaceutical
The Russian pharmaceutical market is facing stagnation these days, which is reflected by its weak results in 2025, when sales grew by only by 0.02% compared to 2024, reaching 4.4 billion packages, reports The Pharma Letter’s local correspondent. 11 February 2026
Pharmaceutical
Russia faces a significant increase in the number of cancelled tenders during drug procurements for state needs, which is mainly due to unfavorable conditions for suppliers and low prices, reports The Pharma Letter’s local correspondent. 5 February 2026
Pharmaceutical
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has spent the past decade trying to make the country a more attractive place to develop and launch innovative drugs and biologics. The most visible signal is the Sakigake designation program, which offers priority consultation and a faster review target for eligible products, plus policy incentives that can support earlier market entry. 2 February 2026
Pharmaceutical
On January 6, 2025, the US Food and Drug Administration (FDA) issued draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products.” The guidance outlines the FDA’s expectations for the use of AI in supporting regulatory assessments of safety, effectiveness, and quality. 2 February 2026
Pharmaceutical
The India-European Union (EU) Free Trade Agreement (FTA) represents a significant opportunity for India's pharmaceutical sector, opening doors to a $572.3 billion market while reinforcing India's global healthcare leadership, reports The Pharma Letter’s India correspondent. 2 February 2026
Pharmaceutical
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. Despite technological and operational advances, startup can often be a bottleneck, resulting in delaying the point at which the first participant can be enrolled. These delays can have significant consequences for trial momentum and overall timelines. 26 January 2026
Pharmaceutical
Ossama Anter Abo Arab, chief executive of MultiCare Egypt for Pharmaceutical Industries, talks with The Pharma Letter about pharmaceutical growth in Egypt. 26 January 2026
Boardroom
Pharmaceutical
French pharma major Sanofi's board of directors has decided not to renew the director mandate of Paul Hudson. As a result, Paul Hudson’s last day as chief executive (CEO) will be on February 17, 2026 at the end of business. 12 February 2026
Pharmaceutical
German CDMO Rentschler Biopharma has appointed Veit Bergendahl as chief operating officer and a member of its executive board, effective from April. 11 February 2026
Pharmaceutical
Canada headquartered Helus Pharma, a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (NSAs), today announced the appointment of Michael Cola as chief executive (CEO), effective immediately. 11 February 2026
Pharmaceutical
Canada based clinical-stage pharma company NervGen Pharma today announced its board of directors has unanimously appointed Dr Adam Rogers, as president and chief executive (CEO), effective immediately. 9 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze